Milestone Pharma reports positive Phase 3 etripamil data for PSVT self-treatment

Milestone Pharmaceuticals Inc.

NODE-303 open-label study: etripamil nasal spray restored sinus rhythm with median time-to-conversion 17.0 minutes.
Efficacy at 30 min was 60%, at 60 min 69.9% — similar to prior double-blinded studies.
Safety consistent: adverse events mostly localized to nasal administration site; frequency decreased with successive episodes.
Data presented at ACC 2024 and published in JACC; supports potential shift in PSVT self-management.
CARDAMYST (conditionally approved brand name) could become first at-the-ready option for acute PSVT if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.